Surrey Heartlands

Joint Formulary & PAD

Relugolix with estradiol and norethisterone acetate - Endometriosis

You are here : Home > Formulary Search > Relugolix with estradiol and norethisterone acetate - Endometriosis

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Blue
Formulations :
  • Tablets
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
NICE
SPC
Restrictions / Comments :
Important

 At least 1 month prescribing by the specialist prior to transfer of care.

A DXA scan is recommended after the first 52 weeks of treatment to verify that the patient does not have an unwanted degree of BMD loss, that exceeds the benefit of treatment. This DXA scan will be organised & performed by the specialist team responsible for the ongoing care of the patient

Documentation

NICE Technology Appraisal
NICE TA1057 - Relugolix-estradiol-norethisterone for treating symptoms of endometriosis - April 2025
Evidence Review
Relugolix_estradiol_northisteone -NICE briefing - July 25.pdf

PAD Profile

ChemicalSubstance :
Relugolix with estradiol and norethisterone acetate
Indication :
Endometriosis
Group Name :
Keywords :
Brand Names Include :
Ryeqo
Important Information :
Latest Additions Date From :
02 Jul 2025
Latest Additions Date To :
Guidelines :
Supporting Documents :
2

Other Indications

Below are listed other indications that Relugolix with estradiol and norethisterone acetate is used to treat.

Other Drugs

Below are listed other drugs that are used to treat Endometriosis.

Committee Recommendations (1)

02 Jul 25 - Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands Integrated Care System Area Prescribing Committee (APC) approves relugolix-estradiol-norethisterone for the treating symptoms of endometriosis as recommended by NICE TA1057

Relugolix-estradiol-norethisterone for this indication will be considered as BLUE (with specialist initiation), with at least 1 month prescribing by the specialist prior to transfer of care.

A DXA scan is recommended after the first 52 weeks of treatment to verify that the patient does not have an unwanted degree of BMD loss, that exceeds the benefit of treatment. This DXA scan will be organised & performed by the specialist team responsible for the ongoing care of the patient.